Drug Shortage Report for TEVA-CANDESARTAN/HCTZ
Report ID | 132657 |
Drug Identification Number | 02395568 |
Brand name | TEVA-CANDESARTAN/HCTZ |
Common or Proper name | CANDESARTAN/HCTZ 32/12.5MG TB |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | CANDESARTAN CILEXETIL HYDROCHLOROTHIAZIDE |
Strength(s) | 32MG 12.5MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 30 |
ATC code | C09DA |
ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2021-01-26 |
Estimated end date | 2021-03-31 |
Actual end date | 2021-03-03 |
Shortage status | Resolved |
Updated date | 2021-03-04 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2021-03-04 | French | Compare |
v3 | 2021-03-04 | English | Compare |
v2 | 2021-01-28 | French | Compare |
v1 | 2021-01-28 | English | Compare |
Showing 1 to 4 of 4